Nagoya City University Psychiatry

sitemap

Clinical Epidemiology & Evidence-Based Psychiatry

Theoretical Works in Clinical Epidemiology

Elamin MB, Flynn DN, Bassler D, Briel M, Alonso-Coello P, Karanicolas PJ, Guyatt GH, Malaga G, Furukawa TA, Kunz R, Schunemann H, Murad MH, Barbui C, Cipriani A & Montori VM (2009) Choice of data extraction tools for systematic reviews depends on resources and review complexity. Journal of Clinical Epidemiology, 62, 506-510.
Guyatt G & Furukawa TA (2008) An illustration of bias and random error. In Users' Guides to the Medical Literature: A Manual for Evidence-Based Clinical Practice (2nd edn). (eds Guyatt G, Rennie D, Meade MO & Cook DJ), pp. 109-112. New York: The McGraw-Hill Companies, Inc.
Furukawa TA, Strauss S, Bucher HC & Guyatt G (2008) Diagnostic tests. In Users' Guides to the Medical Literature: A Manual for Evidence-Based Practice (2nd edn). (eds Guyatt G, Drummond R, Meade MO & Cook DJ), pp. 419-438. New York: The McGraw-Hill Companies, Inc.
Furukawa TA, Jaeschke R, Cook D & Guyatt G (2008) Measurement of patients' experience. In Users' Guides to the Medical Literature: A Manual for Evidence-Based Clinical Practice (2nd edn). (eds Guyatt G, Drummond R, Meade MO & Cook DJ), pp. 249-271. New York: The McGraw-Hill Companies, Inc.
Furukawa TA, Strauss S, Bucher HC & Guyatt G (2008) Diagnostic tests. In Users' Guides to the Medical Literature: Essentials of Evidence-Based Practice (2nd edn). (eds Guyatt G, Drummond R, Meade MO & Cook DJ), pp. 195-222. New York: The McGraw-Hill Companies, Inc.
Furukawa TA, Watanabe N, Omori IM, Montori VM & Guyatt GH (2007) Association between unreported outcomes and effect size estimates in Cochrane meta-analyses. JAMA, 297, 468-470. Paper that changed our practices
Cipriani A, Malvini L, Furukawa TA & Barbui C (2007) Relationship between quality of reports of antidepressant randomized controlled trials and treatment estimates: Systematic review, meta-analysis, and meta-regression analysis. Journal of Clinical Psychopharmacology, 27, 352-356.
Cipriani A, Furukawa TA, Churchill R & Barbui C (2007) Validity of indirect comparisons in meta-analysis. Lancet, 369, 270-271; author reply 271.
Furukawa TA, Barbui C, Cipriani A, Brambilla P & Watanabe N (2006) Imputing missing standard deviations in meta-analyses can provide accurate results. Journal of Clinical Epidemiology, 59, 7-10.
Furukawa TA & Guyatt GH (2006) Sources of bias in studies of diagnostic tests and the diagnostic process. Canadian Medical Association Journal, 174, 481-482.
Furukawa TA, Cipriani A, Barbui C, Brambilla P & Watanabe N (2005) Imputing response rates from means and standard deviations in meta-analysis. International Clinical Psychopharmacology, 20, 49-52.
Furukawa T (2004) Meta-analyses and megatrials: neither is the infallible, universal standard. Evidence-Based Mental Health, 7, 34-35.
Furukawa TA (2004) All clinical trials must be reported in detail and made publicly available. BMJ, 329, 626.
Furukawa TA (2002) Review: placebo is better than no treatment for subjective continuous outcomes and for treatment of pain. Evidence-Based Mental Health, 5, 15.
Furukawa TA, Guyatt GH & Griffith LE (2002) Can we individualize the 'number needed to treat'? An empirical study of summary effect measures in meta-analyses. International Journal of Epidemiology, 31, 72-76.
Furukawa TA, Inada T, Adams CE, McGuire H, Inagaki A & Nozaki S (2002) Are the Cochrane group registers comprehensive? A case study of Japanese psychiatry trials. BMC Medical Research Methodology, 2, 6.
Furukawa TA, Streiner DL & Hori S (2000) Discrepancies among megatrials. Journal of Clinical Epidemiology, 53, 1193-1199.
Furukawa T (1999) Toolbox for evidence-based psychiatry: Cochrane Library, Evidence-Based Mental Health, AHCPR Clinical Practice Guideline, Psychopharmacology Algorithm, APA Practice Guideline. International Clinical Psychopharmacology, 14, 43-44.
Furukawa TA (1999) From effect size into number needed to treat. Lancet, 353, 1680.

Diagnoses & Assessments

Furukawa TA, Shear MK, Barlow DH, Gorman JM, Woods SW, Money R, Etschel E, Engel RR & Leucht S (in press) Evidence-based guidelines for interpretation of the Panic Disorder Severity Scale. Depression and Anxiety.
Kessler RC, Green JG, Gruber MJ, Sampson NA, Bromet E, Cuitan M, Furukawa TA, Gureje O, Hinkov H, Hu CY, Lara C, Lee S, Mneimneh Z, Myer L, Oakley-Browne M, Posada-Villa J, Sagar R, Viana MC & Zaslavsky AM (2010) Screening for serious mental illness in the general populationj with the K6 screening scale: results from the WHO World Mental Health (WMH) survey initiative. International Journal of Methods in Psychiatric Research, 19, 4-
Furukawa TA, Kawakami N, Saitoh M, Ono Y, Nakane Y, Nakamura Y, Tachimori H, Iwata N, Uda H, Nakane H, Watanabe M, Naganuma Y, Hata Y, Kobayashi M, Miyake Y, Takeshima T & Kikkawa T (2008) The performance of the Japanese version of the K6 and K10 in the World Mental Health Survey Japan. International Journal of Methods in Psychiatric Research, 17, 152-158.
Tabuse H, Kalali A, Azuma H, Ozaki N, Iwata N, Naitoh H, Higuchi T, Kanba S, Shioe K, Akechi T & Furukawa TA (2007) The new GRID Hamilton Rating Scale for Depression demonstrates excellent inter-rater reliability for inexperienced and experienced raters before and after training. Psychiatry Research, 153, 61-67.
Furukawa TA, Akechi T, Azuma H, Okuyama T & Higuchi T (2007) Evidence-based guidelines for interpretation of the Hamilton Rating Scale for Depression. Journal of Clinical Psychopharmacology, 27, 531-534.
Furukawa TA & Guyatt GH (2006) Sources of bias in studies of diagnostic tests and the diagnostic process. Canadian Medical Association Journal, 174, 481-482.
Hiroe T, Kojima M, Yamamoto I, Nojima S, Kinoshita Y, Hashimoto N, Watanabe N, Maeda T & Furukawa TA (2005) Gradations of clinical severity and sensitivity to change assessed with the Beck Depression Inventory-II in Japanese patients with depression. Psychiatry Research, 135, 229-235.
Yamamoto I, Nakano Y, Watanabe N, Noda Y, Furukawa TA, Kanai T, Takashio O, Koda R, Otsubo T & Kamijima K (2004) Cross-cultural evaluation of the Panic Disorder Severity Scale in Japan. Depression and Anxiety, 20, 17-22.
Furukawa TA, Kessler RC, Slade T & Andrews G (2003) The performance of the K6 and K10 screening scales for psychological distress in the Australian National Survey of Mental Health and Well-Being. Psychological Medicine, 33, 357-362.
Furukawa TA, Andrews G & Goldberg DP (2002) Stratum-specific likelihood ratios of the general health questionnaire in the community: help-seeking and physical co-morbidity affect the test characteristics. Psychological Medicine, 32, 743-748.
Kojima M, Furukawa TA, Takahashi H, Kawai M, Nagaya T & Tokudome S (2002) Cross-cultural validation of the Beck Depression Inventory-II in Japan. Psychiatry Research, 110, 291-299.
Furukawa TA, Goldberg DP, Rabe-Hesketh S & Ustun TB (2001) Stratum-specific likelihood ratios of two versions of the General Health Questionnaire. Psychological Medicine, 31, 519-529.
Furukawa T & Goldberg DP (1999) Cultural invariance of likelihood ratios for the General Health Questionnaire. Lancet, 353, 561-562.

Treatments

Martin-Sanchez E, Furukawa TA, Taylor J & Martin JL (in press) Systematic review and meta-analysis of cannabis treatment for chronic pain. Pain Medicine.
Cipriani A, Furukawa TA, Geddes J, Malvini L, Signoretti A, Churchill R, McGuire H, Nakagawa A & Barbui C (in press) Does randomised evidence support a first-line antidepressant for adults with acute major depression? A systematic review and meta-analysis. Journal of Clinical Psychiatry.
Watanabe N, Omori IM, Nakagawa A, Cipriani A, Barbui C, McGuire H, Churchill R & Furukawa TA (2010) Safety reporting and adverse-event profile of mirtazapine described in randomized controlled trials in comparison with other classes of antidepressants in the acute-phase treatment of adults with depression: systematic review and meta-analysis. CNS Drugs, 24, 35-53.
Barbui C, Cipriani A, Furukawa TA, Salanti G, Higgins JP, Churchill R, Watanabe N, Nakagawa A, Omori IM & Geddes JR (2009) Making the best use of available evidence: the case of new generation atidepressants. A response to: Are all antidepressants equal? Evidence-Based Mental Health, 12, 101-104.
Omori IM, Watanabe N, Nakagawa A, Akechi T, Cipriani A, Barbui C, McGuire H, Churchill R & Furukawa TA (2009) Efficacy, tolerability and side-effect profile of fluvoxamine for major depression: meta-analysis. Journal of Psychopharmacoogy, 23, 539-550.
Furukawa TA (2009) A stepped-care prevention programme decreased depression and anxiety disorders in elderly patients. Evidence-Based Medicine, 14, 146.
Nakagawa A, Watanabe N, Omori IM, Barbui C, Cipriani A, McGuire H, Churchill R & Furukawa TA (2009) Milnacipran versus other antidepressive agents for depression. Cochrane Database of Systematic Reviews, CD006529.
Omori IM & Wang J (2009) Sulpiride versus placebo for schizophrenia. Cochrane Database of Systematic Reviews, CD007811.
Cipriani A, Santilli C, Furukawa TA, Signoretti A, Nakagawa A, McGuire H, Churchill R & Barbui C (2009) Escitalopram versus other antidepressive agents for depression. Cochrane Database of Systematic Reviews, CD006532.
Cipriani A, La Ferla T, Furukawa TA, Signoretti A, Nakagawa A, Churchill R, McGuire H & Barbui C (2009) Sertraline versus other antidepressive agents for depression. Cochrane Database of Systematic Reviews, CD006117.
Cipriani A, Geddes JR, Furukawa TA, Salanti G & Barbui C (2009) Ranking antidepressants -- Authors' reply. Lancet, 373, 1761-1762.
Cipriani A, Santilli C, Furukawa TA, Signoretti A, Nakagawa A, McGuire H, Churchill R & Barbui C (2009) Escitalopram versus other antidepressive agents for depression. Cochrane Database of Systematic Reviews, CD006532.
Cipriani A, La Ferla T, Furukawa TA, Signoretti A, Nakagawa A, Churchill R, McGuire H & Barbui C (2009) Sertraline versus other antidepressive agents for depression. Cochrane Database of Systematic Reviews, CD006117.
Watanabe N, Churchill R & Furukawa TA (2009) Combined psychotherapy plus benzodiazepines for panic disorder. Cochrane Database of Systematic Reviews, CD005335.
Cipriani A, Furukawa TA, Salanti G, Geddes JR, Higgins JP, Churchill R, Watanabe N, Nakagawa A, Omori IM, McGuire H, Tansella M & Barbui C (2009) Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet, 373, 746-758. Paper that changed our practices
Watanabe N, Omori IM, Nakagawa A, Cipriani A, Barbui C, McGuire H, Churchill R & Furukawa TA (2008) Mirtazapine versus other antidepressants in the acute-phase treatment of adults with major depression: Systematic review and meta-analysis. Journal of Clinical Psychiatry, 69, 1404-1415.
Nakagawa A, Watanabe N, Omori IM, Barbui C, Cipriani A, McGuire H, Churchill R & Furukawa TA (2008) Efficacy and Tolerability of milnacipran in the treatment of major depression in comparison with other antidepressants : A systematic review and meta-analysis. CNS Drugs, 22, 587-602.
Barbui C, Furukawa TA & Cipriani A (2008) Effectiveness of paroxetine in the acute phase treatment of adults with major depression: a systematic re-examination of published and unpublished randomised data. Canadian Medical Association Journal, 178, 296-305.
Watanabe N, Hunot V, Omori IM, Churchill R & Furukawa TA (2007) Psychotherapy for depression among children and adolescents: a systematic review. Acta Psychiatrica Scandinavica, 116, 84-95.
Watanabe N, Churchill R & Furukawa TA (2007) Combination of psychotherapy and benzodiazepines versus either therapy alone for panic disorder: a systematic review. BMC Psychiatry, 7, 18.
Martin JL, Sainz-Pardo M, Furukawa TA, Martin-Sanchez E, Seoane T & Galan C (2007) Review: Benzodiazepines in generalized anxiety disorder: heterogeneity of outcomes based on a systematic review and meta-analysis of clinical trials. Journal of Psychopharmacology, 21, 774-782.
Furukawa T, Watanabe N & Churchill R (2007) Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia. Cochrane Database of Systematic Reviews, CD004364.
Cipriani A, Geddes JR, Furukawa TA & Barbui C (2007) Metareview on short-term effectiveness and safety of antidepressants for depression: an evidence-based approach to inform clinical practice. Canadian Journal of Psychiatry, 52, 553-562.
Cipriani A, Barbui C, Brambilla P, Furukawa T, Hotopf M & Geddes J (2006) Are all antidepressants really the same? The case of fluoxetine: a systematic review. Journal of Clinical Psychiatry, 67, 850-864.
Furukawa TA, Streiner DL, Young LT & Kinoshita Y (2006) Antidepressants plus benzodiazepine for major depression. Cochrane Database of Systematic Reviews.
Furukawa TA, Watanabe N & Churchill R (2006) Psychotherapy plus antidepressant for panic disorder with or without agoraphobia: systematic review. British Journal of Psychiatry, 188, 305-312. Paper that changed our practices
Cipriani A, Brambilla P, Furukawa T, Geddes J, Gregis M, Hotopf M, Malvini L & Barbui C (2005) Fluoxetine versus other types of pharmacotherapy for depression. Cochrane Database of Systematic Reviews, 4, CD004185.
Furukawa T, McGuire H & Barbui C (2003) Low dosage tricyclic antidepressants for depression. Cochrane Database of Systematic Reviews, CD003197.
Geddes JR, Carney SM, Davies C, Furukawa TA, Kupfer DJ, Frank E & Goodwin GM (2003) Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review. Lancet, 361, 653-661. Paper that changed our practices
Inada T, Nozaki S, Inagaki A & Furukawa TA (2003) Efficacy of diazepam as an anti-anxiety agent: meta-analysis of double-blind, randomized controlled trials carried out in Japan. Human Psychopharmacology, 18, 483-487.
Furukawa TA, McGuire H & Barbui C (2002) Meta-analysis of effects and side effects of low dosage tricyclic antidepressants in depression: systematic review. BMJ, 325, 991-995. Paper that changed our practices
Furukawa TA, Streiner DL & Young LT (2001) Is antidepressant-benzodiazepine combination therapy clinically more useful? A meta-analytic study. Journal of Affective Disorders, 65, 173-177.
Furukawa T, Streiner DL & Young LT (2000) Antidepressant plus benzodiazepine for major depression. Cochrane Database of Systematic Reviews, CD001026.